Company profile

Shanghai Allink Biotherapeutics Co., Ltd.

Privately held: no public share price (Founded 2023, funded via a $42M Series A (Nov 2024) plus extensions; venture-backed and privately held. [resolved 2026-08-05 by resolve-null-is-public; source: http://en.allinkbio.com/html/59.html]) · China

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
ALK202
Phase 2
EGFR x c-METSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.